Backed by one of the biggest names in pharma, the studio looks to shake up consumer healthcare markets

HiberCell has acquired genomics analytic services provider Genuity Science, which had previously been bought by WuXi AppTec before being spun off last year.

Bluesail Medical-backed mechanical heart pump developer Tongxin has collected at least $30.8m of series D funding.

National Grid Partners contributed to data protection software provider Baffle's series B round while Axa and Zendesk exited sales enablement platform developer Seismic.

Dexcel Pharma joins second funding round for BrainQ’s artificial intelligence (AI)-based technology.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.

Novartis Venture Fund returned as GentiBio raised money that will support the progress of its type 1 diabetes drug candidate toward clinical trials.

Oxford Sciences Innovation returned to reinvest in the smart echocardiogram technology spinout, helping increase its overall funding to nearly $60m.

Blue Venture Fund led a round that included corporate venturing units GV and Optum Ventures, taking the medical imaging system developer's total funding to almost $60m.